William A. Bertrand, Jr., JD

Bill joined the Ardelyx board of directors in October 2015. He currently serves as the chief operating officer at Adaptimmune Therapeutics. Prior to his role at Adaptimmune, Bill served as the executive vice president, general counsel of Infinity Pharmaceuticals, Inc. From 2013 to 2015, he held a variety of positions with Salix Pharmaceuticals, Ltd., including senior vice president, general counsel, acting chief operating officer, and lastly, general manager of Salix Pharmaceuticals following its acquisition by Valeant Pharmaceuticals International in April 2015. Before that, Bill completed a 12-year career at Medimmune Limited, a biotechnology company and subsidiary of AstraZeneca Plc, serving in numerous roles of increasing responsibility, including as executive vice president and general counsel from 2008 to 2013.

Bill received his B.S. in Biology from Wayne State University and his J.D. from the University of Wisconsin-Madison.